Apellis Pharmaceuticals, Inc. (APLS)
$41.03+0.00%Close
BUYBULL · day 33
Key stats
- Market cap
- $5.3B
- Beta
- -0.25
- P/E (TTM)
- 38.71
- 1W
- +0.00%
- 1M
- +0.39%
- vs SPY 1W
- -0.42%
- vs SPY 1M
- -1.67%
Industry peers
FMP comparable companies · ranked by market cap
- KNSABUYKiniksa Pharmaceuticals International, plc$5.8BBULLQ 23$76.31-0.68%
- CDTXCidara Therapeutics, Inc.$5.6B$221.38
- SRRKSELLScholar Rock Holding Corporation$5.2BCRISISQ 22$43.40-0.59%
- ADPTSELLAdaptive Biotechnologies Corporation$4.8BCRISISQ 6$29.84-3.47%
- CPRXBUYCatalyst Pharmaceuticals, Inc.$3.9BBULLQ 20$31.49+0.00%
- IDYASELLIDEAYA Biosciences, Inc.$3.6BBEARQ 25$38.06-0.14%
- BEAMBUYBeam Therapeutics Inc.$2.6BRECOVERYQ 13$25.67-2.22%
- RXRXBUYRecursion Pharmaceuticals, Inc.$2.5BCRISISQ 1$4.78-8.03%
- MLYSSELLMineralys Therapeutics, Inc.$2.1BCRISISQ 18$23.30-4.88%
- AGIOSELLAgios Pharmaceuticals, Inc.$1.9BRECOVERYQ 4$31.25-3.11%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 23
- VALUE
- 13
- GROWTH
- 61
- GARP
- 12
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC23.8%
REV YoY-
ROE39.7%
EPS YoY-
ROA12.3%
GROSS90
OP15
NET12
[VALUATION]
P/E TTM38.71
P/E FWD-
SECTOR PE20.54
INDUSTRY PE14.03
P/B12.46
P/FCF-
EV/EBITDA29.54
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E114.66
ALTMAN Z-
CURR RATIO3.63
ND/EBITDA-
BETA-0.25
Company news
Loading headlines…
FAQ
- What is LOPJLB’s current signal on APLS?
- LOPJLB’s latest quantitative signal on Apellis Pharmaceuticals, Inc. (APLS) is BUY in a BULL regime. Signals are updated daily.
- What market regime is APLS in?
- Apellis Pharmaceuticals, Inc. (APLS) is currently classified in the BULL HMM market regime on LOPJLB.
- What does Apellis Pharmaceuticals, Inc. (APLS) do?
- Apellis Pharmaceuticals, Inc. is an actively operating biopharmaceutical enterprise dedicated to the discovery, advancement, and commercialization of therapeutic agents. Its core strategy involves modulating the complement system to address various autoimmune and inflammatory conditions. The company's primary investigational compound, pegcetacoplan, is currently undergoing Phase III clinical ev…